Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Biobanking Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global biobanking market size reached US$ 53.3 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 77.6 Billion by 2027, exhibiting a CAGR of 6.46% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Biobanking refers to the process of analyzing and storing information of human biospecimens, which are collected from healthy volunteers or people with a particular condition. This information is used in research and academic studies to improve the understanding of health and different diseases.
Presently, modern biobanks have large-scale analysis of specific disease biomarkers, which include biological or digital material with well-annotated clinical and biological data. They provide a basis for improving personalized medical approaches wherein effective biomarker identification is crucial for disease diagnosis and prognosis.
Biobanking Market Trends:
Biobanking nowadays is gaining widespread adoption in collecting high-quality and well-annotated human biospecimens, understanding the pathogenic mechanisms, and identifying therapeutic targets of coronavirus disease (COVID-19). Apart from this, due to the increasing prevalence of new infectious and chronic diseases, there is a rise in the demand for biobanking to develop diagnostics that can accurately and quickly identify pathogens.
This can also be accredited to the growing aging population, in confluence with the escalating demand for regenerative medicine and personalized treatment across the globe.
Moreover, developments in genomics, metagenomics, proteomics, disease biology, bioenergy, environmental remediation, and allied fields are contributing to the market growth. Besides this, health agencies of numerous countries are investing in virtual biobank network models that offer a faster and sustainable solution. These network models offer electronic databases that help investigators to locate biospecimens and data mining from multiple biobanks.
Furthermore, leading market players are offering a diverse portfolio of biobanking products and services that enable sharing of insights and critical information to advancing science. These innovations are projected to strengthen the growth of the market in the coming years.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Brooks Automation Inc., Bay Biosciences LLC, Boca Biolistics, Ctibiotech, Cureline Inc., Firalis, Greiner Bio-One International GmbH, Hamilton Company, Merck KGaA, ProteoGenex Inc., Thermo Fisher Scientific Inc. and VWR Corporation (Avantor Inc.).
Key Questions Answered in This Report
- What was the size of the global biobanking market in 2021?
- What is the expected growth rate of the global biobanking market during 2022-2027?
- What are the key factors driving the global biobanking market?
- What has been the impact of COVID-19 on the global biobanking market?
- What is the breakup of the global biobanking market based on the specimen type?
- What is the breakup of the global biobanking market based on the biobank type?
- What is the breakup of the global biobanking market based on the application?
- What is the breakup of the global biobanking market based on the end user?
- What are the key regions in the global biobanking market?
- Who are the key players/companies in the global biobanking market?
| Report Attribute | Details |
| No. of Pages | 145 |
| Forecast Period | 2021 - 2027 |
| Estimated Market Value (USD) in 2021 | $53.3 Billion |
| Forecasted Market Value (USD) by 2027 | $77.6 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Biobanking Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Specimen Type
6.1 Blood Products
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Solid Tissue
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Cell Lines
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Nucleic Acid
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Biobank Type
7.1 Population-based Biobanks
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Disease-oriented Biobanks
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Application
8.1 Therapeutics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Research
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by End User
9.1 Academic Institutions
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Pharma and Biotech Companies
9.2.1 Market Trends
9.2.2 Market Forecast
10 Market Breakup by Region
11 SWOT Analysis
12 Value Chain Analysis
13 Porters Five Forces Analysis
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Brooks Automation Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.2 Bay Biosciences LLC
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.3 Boca Biolistics
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.4 Ctibiotech
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.5 Cureline Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Firalis
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Greiner Bio-One International GmbH
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Hamilton Company
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.9 Merck KGaA
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 ProteoGenex Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.11 Thermo Fisher Scientific Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 VWR Corporation (Avantor Inc.)
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
For more information about this report visit https://www.researchandmarkets.com/r/sxbzps
Attachment
